

ALTERNATE HEALTH ANNOUNCES NOTICE OF CHANGE OF AUDITOR

Toronto, ON, June 2, 2017 – <u>Alternate Health Corp.</u> (CSE:AHG, OTC:AHGIF) wishes to announce that its Board of Directors have approved a change of the Company's auditors from Scarrow Yurman & Co. Professional Corporation ("Scarrow") to BDO Canada LLP ("BDO").

At the request of the Company, Scarrow has resigned as auditor of the Company effective May 23, 2017. The Audit Committee and the Board of Directors of the Company have appointed BDO as the successor auditor in their place effective May 23, 2017. The Company has sent a Change of Auditor Notice (the "Notice") to each of Scarrow and BDO, and has received a letter from each addressed to the securities commissions in each of British Columbia, Alberta, and Ontario (the "Commissions") stating they agree with the information contained in the Notice. A copy of each letter from Scarrow and BDO addressed to the Commissions will be filed on SEDAR with a copy of the Notice.

There were no disagreements or unresolved issues with Scarrow on any matter of audit scope or procedure, accounting principles or policies, or financial statement disclosure. It is the Company's opinion that there have been no reportable events, (as defined in National Instrument 51-102 (Part 4.11)) between the Company and Scarrow and Scarrow did not have any reservation in their auditors' report for the financial statements for the Company's last two fiscal years or for any period subsequent to the date the most recent audit report was issued and preceding the date hereof.

Alternate Health's CEO, Dr. Jamison Feramisco stated: "I would like to express our sincere gratitude to Scarrow on behalf of the shareholders and the board of directors, and we look forward to working with BDO going forward".

About Alternate Health Corp:

Alternate Health Corp. is a technology-focused healthcare company, driving innovation in complementary medicine, clinical research, technology and medical cannabis.

Based on a portfolio of clinical laboratories, research studies and medical software, Alternate Health invests in research, testing and production for the medicinal and therapeutic use of Cannabidiol (CBD) and other cannabinoids. Leveraging the company's assets in exclusive patents and partnerships, Alternate Health positions itself to be the global authority on the science, manufacturing and administration of medical cannabis.

Contact:

Graham Buck: <u>Graham.Buck@finsbury.com</u> Alex Kovtun: Alex.Kovtun@finsbury.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements